Previous 10 | Next 10 |
COVID-19 antibody therapies developed by Eli Lilly (NYSE:LLY) and Regeneron (NASDAQ:REGN) lose most of their activity when exposed to the newly detected Omicron variant of coronavirus, a lab-based study conducted by a group of German researchers has found. The antibody therapies in question, ...
For 2022, I am going to focus on those companies poised to benefit from the tragic COVID-19 pandemic. I maintain that SARS-CoV-2 will be with us for a long time. As for the proposed drug price legislation in BBBA, it would impact biologics (high cost medications) only near the end of ...
Vir Biotechnology (NASDAQ:VIR) has begun a phase 2 trial examining a combination of VIR-2218, Gilead Sciences' (NASDAQ:GILD) selgantolimod and Bristol-Myers Squibb's (NYSE:BMY) Opdivo for chronic hepatitis B virus ("HBV"). Patients who have already received HBV treatment may also receiv...
– Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV – SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in...
4 Top Health Care Stocks Worth Watching Now Health care stocks have and continue to make headway in the stock market now amidst the current pandemic. From firms directly dealing with the global coronavirus outbreak to day-to-day health care providers, investors have plenty o...
SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations ...
– New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus updated to bioRxiv – Data build on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-1...
As scientists raced to uncover further details on the impact of the newly found Omicron variant on vaccine-driven immunity, COVID-19 antibody developers dominated best-performing healthcare stocks this week. While the sector became the fifth-worst performer in the S&P 500D dragged by the ...
CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Omicron in America The first Omicron case identified in the United States kicked selling into high gear on Wall Street yesterday. Stocks began the previous...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...